Abstract：
Generalized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flares, as demonstrated in clinical trials.
摘要：
广义脓疱型牛皮癣(3GPP)是一种罕见的，具有特征性皮肤和全身表现的免疫介导的炎性疾病。白细胞介素36受体拮抗剂（IL36RN）基因的突变与其发病机理有关。Spesolimab是一种选择性抑制白介素-36的新型系统性生物疗法。它最近被加拿大卫生部和美国FDA批准用于治疗成人中的3GPP耀斑。1期和2期研究的结果是有希望的。在这里，我们回顾了spesolimab治疗3GPP耀斑的疗效和安全性，正如临床试验所证明的那样。
